All News

RPLND alone provides up to 90% cure in patients with low-volume, low-risk testis cancer and eliminates the risk of teratoma and viable tumor in the retroperitoneum in those with high-risk disease.

New Products

Results of a milestone study on the use of an experimental form of immunotherapy may usher in a new era in the management of androgen-independent prostate cancer.

Ureteroscopy is more effective than extracorporeal shock wave lithotripsy for the treatment of proximal ureteral stones.

With the current physician shortage, if you plan to bring another physician into the practice, you'd better do it right.

Dutasteride (Avodart) reduces the risk of biopsy-detectable prostate cancer by about one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers. In addition, the 5-alpha-reductase inhibitor significantly enhances the utility of PSA as a diagnostic test for prostate cancer.

Findings from a multicenter, randomized, double-blind, placebo-controlled study are consistent with previously reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH.

The traditional prescribing process can be inefficient. We help you understand the definition of e-prescribing, the case for e-prescribing, and how to get started.

Prostate cancer research deserves the same level of government commitment that other forms of cancer receive, even those that affect young children.

Sealing the percutaneous tract is not necessary if patients have been rigorously selected for tubeless percutaneous nephrolithotomy.

Although payment is a nice incentive, it is not the main reason to participate in the Physician Quality Reporting Initiative.

Watson Pharmaceuticals, Inc. has filed an abbreviated new drug application with the FDA to market its darifenacin hydrobromide extended-release 7.5-mg and 15-mg product prior to the expiration of a patent owned by Novartis AG.

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45%, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from the University of Texas M.D. Anderson Cancer Center, Houston.

An investigational drug called MDV3100 has shown significant promise in lowering PSA levels in men with advanced prostate cancer who have no other option for cure.

Large numbers of physician extenders (PEs)?physician assistants and nurse practitioners?have been hired by general surgery residency programs during the last 5 years to bolster the resident education experience, and these professionals continue to be in demand, according to a recent study.

Prompted by reports of serious adverse events, the FDA announced that safety label changes, including a boxed warning and a Risk Evaluation and Mitigation Strategy, are necessary for all botulinum toxin products.

Nephron-sparing treatments, including partial nephrectomy, thermal ablation, and active surveillance, minimize risk of chronic kidney disease and cardiovascular disease and are viable options for patients with early-stage kidney tumors, according to a new clinical guideline issued by AUA.

360 Network

Results of a population-based, case-control study suggest there may be an association between marijuana use and the occurrence of testicular germ cell tumors (TGCTs), researchers from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, reported.

President Obama's 2010 budget proposal, with its $630 billion down payment on health care reform over the next decade, appears to contain significant good news for urologists, but never has it been more true: the devil is in the details.